Low-grade serous ovarian cancer, or LGSOC, is a rare form of ovarian cancer that affects around 6,000 to 8,000 women in the U.S. and approximately 80,000 globally. This cancer which is highly recurrent and less sensitive to chemotherapy has a median survival of approximately ten years. The current standard treatment for this disease involves hormone therapy and chemotherapy. However, there are no therapies specifically approved by the FDA for LGSOC.
The stock we are bringing to your attention today is Verastem Inc. (VSTM), which is developing a drug for low-grade serous ovarian cancer.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.